Recruiting
Phase 1

IM-TMI, Fludarabine & Melphalan

Sponsor:

University of Chicago

Code:

NCT02333162

Conditions

Previously Treated Myelodysplastic Syndrome

Recurrent Adult Acute Lymphoblastic Leukemia

Recurrent Adult Acute Myeloid Leukemia

Recurrent Hematologic Malignancy

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Fludarabine Phosphate

Melphalan

Intensity-Modulated Radiation Therapy

Total Marrow Irradiation

Allogeneic Hematopoietic Stem Cell Transplantation

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-09. This information was provided to ClinicalTrials.gov by University of Chicago on 2025-02-05.